Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glutamine supplement may tame insulin resistance and IBS in obesity

NCT ID NCT04883515

Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking glutamine, an amino acid, for 8 weeks can improve insulin resistance and reduce irritable bowel syndrome (IBS) symptoms in obese patients. 110 participants will receive either glutamine or a protein powder placebo. Researchers will measure changes in blood sugar control and gut function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
glutamine (an amino acid)
What this could lead to
If it works, this could point toward a simple dietary supplement to help control blood sugar and reduce gut discomfort in people with obesity.
What could go wrong
This is an early-stage trial with only 110 participants. The supplement may not improve insulin resistance or IBS symptoms, and results may not apply to all obese patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged from 18 to 65 years * Patient with h grade II or III obesity (body mass index equal or higher than 35 kg/m2) * Patient with insulino-resistance (fasting glycaemia ≥ 1g/l et \< 1.26 g/l) * Patient with irritable bowel syndrome (Rome IV criteria ≥ 2) Exclusion Criteria: * Patient with Known liver insufficiency (prothrombin time \< 70%) * Patient with Known kidney failure (GFR \< 60 ml/mn) * Patient with Known intestinal diseases such as inflammatory bowel diseases * Vomiting patients (≥ 1/ day) during the last 4 weeks * Patient Previously received bariatric surgery or digestive surgery * Patient Using laxatives or protein powder during the 4 last weeks * On going Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance irritable bowel syndrome Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rouen University Hospital

    RECRUITING

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.